- University of Illinois College of Medicine at Chicago, Chicago, IL – MD
- University of Wisconsin Hospital and Clinics – Residency in Internal Medicine (ABIM Research Pathway)
- University of Wisconsin Hospital and Clinics – Fellowship in Medical Oncology (ABIM Research Pathway)
Dr. Joshua Lang is a faculty member in the Division of Hematology, Medical Oncology and Palliative Care in the Department of Medicine. He is the co-director of the internal medicine residency’s Physician-Scientist Training Program (PSTP) and a lecturer in several didactic series for medical students, internal medicine residents and hematology/oncology fellows.
Dr. Lang is also the director of the UW Carbone Cancer Center’s circulating biomarker core and liquid biospecimen team, the co-leader of its tumor microenvironment program, and the clinical co-chair of its precision medicine molecular tumor board. He is a member of the American Society of Clinical Oncology (ASCO), the Society for Immunotherapy of Cancer, and the American Association of Cancer Research. Dr. Lang has received an ASCO Merit Award; a University of Wisconsin Helen Dickie Fellows Research Award; a Prostate Cancer Foundation Young Investigator Award; a Department of Medicine Puestow Junior Faculty Research Award; and a Division of Hematology, Medical Oncology and Palliative Care Award for Research Excellence.
Dr. Lang is a medical oncologist who specializes in genitourinary (bladder, kidney, prostate and testicular) cancer.
Dr. Lang has research interests in translational biomarker therapeutics for prostate cancer. He is the lead principal investigator on the multi-PI Department of Defense Prostate Cancer Research Program, and the PI of a Prostate Cancer Foundation-funded project to investigate therapeutic targeting of AR-variant prostate cancer with a novel antibody drug conjugate. Dr. Lang also leads clinical trials that evaluate circulating tumor cells in solid tumor malignancies, efficacy of IMMU-132 in patients with metastatic castration-resistant prostate cancer and chemohormonal therapy in high-risk and oligo-metastatic prostate cancer.